Estimated impact of long‐acting injectable PrEP in South Africa: a model comparison analysis

Abstract Introduction Long‐acting injectable cabotegravir (CAB‐LA) demonstrated superiority to daily tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for human immunodeficiency virus (HIV) pre‐exposure prophylaxis (PrEP) in two clinical trials. This analysis projects the impact of expanding PrE...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Sarah E. Stansfield, Mia Moore, Lise Jamieson, Gesine Meyer‐Rath, Leigh F. Johnson, David Kaftan, Anna Bershteyn, Jennifer Smith, Valentina Cambiano, Loveleen Bansi‐Matharu, Andrew Phillips, Jesse Heitner, Ruanne V. Barnabas, Brett Hanscom, Deborah J. Donnell, Marie‐Claude Boily, Dobromir Dimitrov
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Wiley 2025-07-01
Saila:	Journal of the International AIDS Society
Gaiak:	adherence CAB‐LA HIV prevention modelling pre‐exposure prophylaxis South Africa
Sarrera elektronikoa:	https://doi.org/10.1002/jia2.26453
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!